• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Merck (MRK) Q2 Earnings and Revenues Top Estimates

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 30, 2024 at 06:42: PM
via Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago. These figures are adjusted for non-recurring items.

article source
 

<



Similar threads

cafead
Merck (MRK) Q2 Earnings and Revenues Surpass Estimates
Replies
0
Views
121
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Can Merck (MRK) Keep the Earnings Beat Streak Alive in Q3?
Replies
0
Views
181
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck (MRK) to Report Q3 Earnings: What&#039;s in the Cards?
Replies
0
Views
141
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Why Merck (MRK) Might Surprise This Earnings Season
Replies
0
Views
154
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck (MRK) Keytruda Ok&#039;d by FDA for Expanded Cervical Cancer Use
Replies
0
Views
303
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote